Form 4 for PCVX Vaxcyte, Inc.
Accepted 2025-02-19 00:00:00 ET · period of report 2025-02-18 · accession 0001649094-25-000014 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-19 | 2025-02-18 | PCVX | GUGGENHIME ANDREW | Pres AND CFO | M - OptEx | $5.35 | +8,000 | 117.5K | +7% | +$42.8K |
| DM | 2025-02-19 | 2025-02-18 | PCVX | GUGGENHIME ANDREW | Pres AND CFO | S - Sale+OE | $83.85 | -8,000 | 109.5K | -7% | -$670.8K |
| D | 2025-02-19 | 2025-02-18 | PCVX | GUGGENHIME ANDREW | Pres AND CFO | M - OptEx | $0.00 | -8,000 | 246.8K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-18 | M | A | 8,000 | $5.35 | 117,491 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-18 | S | D | 6,182 | $83.64 | 111,309 | D | — | — | (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $83.17 to $84.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2025-02-18 | S | D | 1,818 | $84.58 | 109,491 | D | — | — | (F3) The price reported is a weighted-average price. The shares were sold at prices ranging from $84.125 to $84.985. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 4 | Derivative | Stock Option (right to buy) | 2025-02-18 | M | D | 8,000 | $0.00 | 246,827 | D | $5.35 · — to 2030-05-11 | 8,000 Common Stock | (F4) Option is fully vested and exercisable |